is a Contract Development and Manufacturing Organization (CDMO), established in 1994. Over the years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions and semi-solid drug products We work hand-in-hand with our clients to customize our services to meet their needs. From full turn-key development projects to collaborative highly, we can adapt to fit your operational requirements. We have been favorably inspected by the EMA, FDA and Health Canada, and manufacturing products for markets around the globe.



Product Development Services


With a team of project managers and subject-matter-experts and in developing and supporting regulatory approval of products at various stages of development (IND, NDA, 505 (b) (2), ANDA). Groupe PARIMA can meet your product development and site-transfer needs based on the status of your project. Our experts in formulation development, scale-up process, analytical method development & validation and packaging, will see your product through initial development phases until completion of process validation, providing you with a single point of contact for all steps of the project. 

Expertise in formulation development

Liquids, Suspensions, Creams, Lotions, Gels, Ointments, Pastes, handling of low flash point products and processes

Different stages of activities

  • Basic formulation
    • De novo formulation
    • Reverse engineering
    • Equivalence to reference drug products
    • Raw material sourcing for cGMP Production
    • Effectiveness and stability of formulations
    • Identification of critical characteristics
    • Selection of packaging components
  • Process development
    • Laboratory, pilot, and cGMP clinical trial materials Commercial scale cGMP
    • Development and optimization using QbD
    • Documentation and reporting to support regulatory filings
    • Development of packaging process (primary and secondary)
    • Stability and transportation studies
  • Supply of clinical and pre-clinical batches
    • Small scale productions for pre-clinical studies
    • Supply of cGMP clinical material (Phases I-III)
    • Excess product stored on-site for future studies
    • Stability studies
    • Customized packaging and labeling
  • Commercial validation
    • Artwork preparation
    • Sourcing of all sales packaging material
    • Complete manufacturing, holding, packaging and cleaning validation
    • Stability studies


Commercial Manufacturing Services


Groupe PARIMA offers contract manufacturing and packaging services to customers throughout the world. With manufactured products for markets located on all five continents, we have a global reach. Our services include full turn-key service, as well as for customer arrangements who prefer to provide some of the material.

Currently, Groupe PARIMA produces a wide-range of business products, with the following applications:

  • Angina pectoris (oral spray)
  • Acne vulgaris (cleanser, towelette, frost)
  • Constipation (oral liquid)
  • Cough and fever treatments (oral liquid)
  • Dermatitis and eczema (cream, lotion, ointment)
  • Dry hands (lotion, cream)
  • Erectile dysfunction (cream)
  • Fungal Infections (liquid)
  • Headaches (oral liquid)
  • Hemorrhoids (cream)
  • Herpes simplex infection (ointment)
  • Joint inflammation (oral suspension)
  • Musculoskeletal pain (cream)
  • Sunscreen products (SPF 30-50 +, cream, lotion)



Our 66,000 square foot modern facility is equipped with a wide-range of manufacturing equipment that allows us to handle all kinds of semi-solids, liquids and suspensions.

Trading spread over manufacturing suites, we can manufacture your drug products on the following scales:

  • 5 kg to 2500 kg: Creams, Lotions, Gels, Ointments, High Viscosity Pastes and high-SPF sunscreen products
  • 5 kg to 4000 kg: liquids, syrups, suspensions
  • Fully jacketed tanks allow temperature control between 2 ºC and 95 ºC
  • Tanks are equipped with sweep, counter-sweep and Homogenizers
  • Secondary manufacturing equipment is available (eg, Lightnin Mixers, Rotosolver, Colloid Mills, APV)

In addition to capabilities thesis, we-have a dedicated explosion-proof manufacturing facility specifically designed to handle manufacturing of low-flash point of mixtures (eg, high-alcohol happy gels and liquids).

  • 1D1 rated room
  • Inert gas blanketing
  • Amber lighting for light-sensitive products
  • Manufacturing volumes of 5 kg to 1600 kg



Groupe PARIMA has a dedicated packaging suite equipped with 12 different packaging lines to meet your needs for all types of primary and secondary packaging. Depending on projected annual volumes, we can offer different levels of automation to provide you with the most cost-effective options for your product.

  • Bottles and jars 5 ml, 1,000 ml - plastic and glass
  • Sprays (including metered-dose) 5 mL -150 mL
  • Tubes 3 mL - 350 mL plastic, laminate and metal
  • Syringe (non-sterile applicators)
  • Sachets 1 mL - 15mL
  • Towelettes 1 mL - 15 mL
  • Bags 1 mL - 15 mL
  • Bag-on valve

Analytical Services


Our laboratory is fully equipped to perform all release and stability testing. From state-of-the-art LCMS analysis to microbiology and more routine physical tests, Groupe PARIMA can perform a wide-range of analysis to fit your needs. Our chromatography instruments are all powered by the Empower 3 software, and all analytical results are kept in our LIMS system.

Groupe PARIMA has on-site stability chambers to perform all typical ICH stability testing, including IV-b Zone status and low temperature (2-8 ° C for cold-chain products).

Analytical chemistry equipment

  • Agilent and Waters HPLCs and UPLCs
  • Agilent GC with Head Space
  • Waters LCMS
  • IVRT (Franz cells) – (Hanson)
  • Laser based particle sizing (Mastersizer 3000)
  • Based laser droplet sizing (nasal and oral sprays, Spraytech)
  • Shimadzu TOC
  • Agilent dissolution apparatus
  • IR and UV spectrometers
  • Viscometers
  • Microscope
  • Fully equipped for --other physical tests

Microbiology Tests Performed On-Site

  • Total aerobic count (USP <61>)
  • Yeast and mold (USP <61>)
  • Specific organisms (USP <62>)
  • Microorganism identification
  • Antimicrobial effectiveness test (USP <51>)

Stability conditions

  • Long-term (25 ° C / 60% RH)
  • Intermediate (30 ° C / 65% RH)
  • Accelerated (40 ° C / 75% RH)

IV-B area

  • 30 ° C / 75% RH

Cold-chain products

  • 2-8 ° C

About us



Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO), established in 1994. For over 25 years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions and semi-solid drug products. We work hand-in-hand with our customers to customize our services to meet their needs. From full turn-key services to highly collaborative development projects, we can adapt to fit your operational requirements.


With products manufactured for markets located on all five continents, we have a global reach. Our client base ranges from small and start-up companies to virtual wide pharmaceutical companies headquartered around the globe. We have been favorably inspected by the EMA, FDA and Health Canada.


The management team is supported by a staff of professionals with a wide-range of expertise and experience including Chemists, Biochemists, Microbiologists, Engineers, and highly qualified operators.



We have numerous positions available in the following departments:
Operations, Quality Assurance, Product Development and Administration.

Click here for more information.

Please send your CV to this email.




FDA Registration Number: 3003773810
NDC Labeler Code: 65179
Health Canada Drug Establishment Licence: 100062-A
Licenced by Health Canada to Produce NPN and Homeopathic products
Generic Drug User Fee Amendment (GDUFA) Compliant


Groupe PARIMA inc.
4450 Rue Cousens
Saint-Laurent QC H4S 1X6


For general inquiries

New Business Projects Inquires or +1.514.338.3780





PBOA Praises Enactment of FDARA


August 18, 2017 – Ringwood, NJ – The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, is pleased that H.R. 2430, the FDA Reauthorization Act (FDARA), has been signed into law, renewing four major user fee agreements between industry and FDA for FY2018 to FY2022.
PBOA president Gil Roth issued the following statement:
“A year ago, industry ratified the second iteration of Generic Drug User Fee Amendments (GDUFA II), and today I commend the White House for signing it into law via FDARA. GDUFA II will empower ...   FOR MORE FOLLOW THIS LINK: http://www.pharma-bio.org/news/pboa-praises-enactment-of-fdara/


Groupe PARIMA Joins PBOA


Pharma & Biopharma Outsourcing Association (PBOA), the trade association for CMOs and CDMOs, as a General Member.  Read the news release.

Groupe PARIMA Appoints Vice-President, Product Development


Groupe PARIMA is pleased to announce the appointment of Alain Desjardins, PhD as VP of Product Development.
“Dr. Desjardins brings considerable experience in product development and process validation, as well as a breath of scientific expertise, which includes not only semi-solid and liquid drug products, but also solid and sterile dosage forms,” said, Dr. Cantin. “I am confident he will implement innovative development strategies that will enable us to fully leverage our extensive resources and long-standing expertise to further meet our clients’ evolving needs in the global market.”  A pharmaceutical industry veteran, Alain most recently served as the Director of Project Management at Groupe PARIMA. During the 20 years prior to that, he held Product Development positions of increasing responsibilities at Pharmascience, Valeant and Sandoz.  Alain holds a PhD degree in Chemistry from McGill University in Montreal. This appointment is a further commitment from Groupe PARIMA to expand its presence in Product Development for global markets. “As a world class CDMO provider, Groupe Parima is already is uniquely positioned to help its clients seize opportunities all over the world. Alain’s wealth of knowledge and expertise will enhance our already strong development position.”

Since 2013, Groupe PARIMA’s contract Product Development segment business has experienced exceptionally strong growth driven by both small biotech companies as well as large pharma customers. Our clients, located all around the world, seek Groupe PARIMA’s expertise in the development of topical products.  To support this significant increase in Product Development demand, Groupe PARIMA has invested heavily in the acquisition of new laboratory and scale-up equipment and tripled the Product Development headcount by hiring chemists, engineers and projects managers.

Groupe Parima will be at DCAT Week 2016


Groupe Parima will be participating in DCAT week (New York City, March 14-17th), one largest gatherings in the world for pharmaceutical and related industries. To schedule a meeting with us at DCAT, please click on the following link (Meet at DCAT). We look forward to meeting you!

Come and Meet Us at CPhI Worldwide in Madrid


Please come and meet us at CPhI Worldwide 2015  at the IFEMA - Feria de Madrid on October 13th to 15th. We will be available for meetings at your convenience during the event. To set up an appointment, use the following link (CPhI 2015) or contact us at bd@groupeparima.com. We look forward to meeting you.

Come and Meet Us at Contract Pharma 2015


Please come and meet us at Contract Pharma 2015 Contracting and Outsourcing Conference and Tabletop Exhibition event at the Hyatt Regency in New Brunswick, NJ on September 17th and 18th. We will be at booth # 78 on September 17th and available for meetings at your convenience in NY/NJ during that entire week. To set up an appointment, use the following link (Contract Pharma 2015). We look forward to meeting you!

Groupe PARIMA Appoints President


Groupe PARIMA announces today the appointment of Louis-David Cantin as President of the company. Since joining Groupe PARIMA in 2013, Mr. Cantin has been instrumental in leading the triple-digit growth of the Product Development business. In his new role, he will bring his 15 years of pharmaceutical R&D and business management experience to complete the transformation of Groupe PARIMA into a word class integrated pharmaceutical development and manufacturing organization.
Claude Mongrain, founder of Groupe PARIMA, will remain as CEO of the company. Mr. Mongrain will focus his activities on conducting business development throughout the world, establishing strategic partnerships and evaluating various growth opportunities.
Groupe PARIMA is a Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of pharmaceutical products as liquids, suspensions, semi-solids and sprays.  With licenses from Health Canada and the US-FDA, Groupe PARIMA manufactures and ships products to all five continents.  Groupe PARIMA clients range from small startup and virtual companies to global pharmaceutical companies located outside Canada.

Meet with us at 2015 BIO International Convention


Groupe Parima will be participating in 2015 BIO International Convention (Philadelphia, June 15-18th), one largest gatherings in the world for biotechnology. To schedule a meeting with us at BIO, please click on the following link (Meet at BIO 2015) or use the BIO partnering platform. We look forward to seeing you! 



Sign up to stay in touch!

Get interesting news and updates delivered to your inbox.

© 2014 Groupe Parima
All rights reserved.